Taysha Gene Therapies annual current ratio
2020
2021
2022
2023
2024
2025
Taysha Gene Therapies Current Ratio Growth & History (TSHA)
Taysha Gene Therapies's current ratio was 12.23 for fiscal 2025.
View full Taysha Gene Therapies company overviewTaysha Gene Therapies annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 12.23 | 6.81 | +125.62% |
| 2024 | 2024-12-31 | 5.42 | 1.34 | +32.91% |
| 2023 | 2023-12-31 | 4.08 | 2.54 | +165.53% |
| 2022 | 2022-12-31 | 1.54 | −1.55 | −50.21% |
| 2021 | 2021-12-31 | 3.08 | −33.09 | −91.47% |
| 2020 | 2020-12-31 | 36.17 | — | — |
Taysha Gene Therapies quarterly current ratio
As of Dec 31, 2019
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 17.76 | 5.29 | +42.39% |
| Q1 2026 | 2026-03-31 | 14.04 | 8.69 | +162.44% |
| Q4 2025 | 2025-12-31 | 12.23 | 6.81 | +125.62% |
| Q3 2025 | 2025-09-30 | 10.48 | 4.97 | +90.23% |
| Q2 2025 | 2025-06-30 | 12.48 | 7.25 | +138.92% |
| Q1 2025 | 2025-03-31 | 5.35 | 1.97 | +58.32% |
| Q4 2024 | 2024-12-31 | 5.42 | 1.34 | +32.91% |
| Q3 2024 | 2024-09-30 | 5.51 | 4.56 | +478.43% |
| Q2 2024 | 2024-06-30 | 5.22 | 4.15 | +388.68% |
| Q1 2024 | 2024-03-31 | 3.38 | 2.05 | +154.38% |
| Q4 2023 | 2023-12-31 | 4.08 | 2.54 | +165.53% |
| Q3 2023 | 2023-09-30 | 0.95 | −0.35 | −26.63% |
| Q2 2023 | 2023-06-30 | 1.07 | −0.72 | −40.26% |
| Q1 2023 | 2023-03-31 | 1.33 | −0.87 | −39.56% |
| Q4 2022 | 2022-12-31 | 1.54 | −1.55 | −50.21% |
| Q3 2022 | 2022-09-30 | 1.30 | −3.27 | −71.56% |
| Q2 2022 | 2022-06-30 | 1.79 | −5.51 | −75.50% |
| Q1 2022 | 2022-03-31 | 2.20 | −10.44 | −82.61% |
| Q4 2021 | 2021-12-31 | 3.08 | −33.09 | −91.47% |
| Q3 2021 | 2021-09-30 | 4.56 | −19.46 | −81.01% |
| Q2 2021 | 2021-06-30 | 7.30 | — | — |
| Q1 2021 | 2021-03-31 | 12.64 | — | — |
| Q4 2020 | 2020-12-31 | 36.17 | 36.07 | +36073.24% |
| Q3 2020 | 2020-09-30 | 24.02 | — | — |
| As of Dec 31, 2019 | 2019-12-31 | 0.10 | — | — |
Taysha Gene Therapies current ratio trends
Over the last five fiscal years, Taysha Gene Therapies's current ratio decreased from 36.17 to 12.23, a change of −23.95. The latest reported quarter, Q2 2026, shows 17.76.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Taysha Gene Therapies source filings ↗